Toll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1β in Mice

Gastroenterology

Volumn 139, Issue 1, 2010, Pages

  Miura, Kouichi ^a,b   Kodama, Yuzo ^a   Inokuchi, Sayaka ^a   Schnabl, Bernd ^a   Aoyama, Tomonori ^a   Ohnishi, Hirohide ^b   Olefsky, Jerrold M ^a   Brenner, David A ^a   Seki, Ekihiro ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bacterial DNA; Bambi; Nonalcoholic Fatty Liver Diseases; Toll Like Receptors

Indexed keywords

INTERLEUKIN 1BETA; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CONTROLLED STUDY; GENE EXPRESSION; HISTOPATHOLOGY; INSULIN RESISTANCE; KUPFFER CELL; LIVER FIBROSIS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STELLATE CELL; WESTERN BLOTTING;

EID: 77953891627     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.03.052     Document Type: Article

References (52)

1. Browning J.D., and Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114 (2004) 147-152
2. Marra F., Gastaldelli A., Svegliati Baroni G., et al. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14 (2008) 72-81
3. Maher J.J., Leon P., and Ryan J.C. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology 48 (2008) 670-678
4. Rivera C.A., Adegboyega P., van Rooijen N., et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 47 (2007) 571-579
5. Bataller R., and Brenner D.A. Liver fibrosis. J Clin Invest 115 (2005) 209-218
6. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 134 (2008) 1655-1669
7. Kawai T., and Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 21 (2009) 317-337
8. Seki E., and Brenner D.A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 48 (2008) 322-335
9. Szabo G., Dolganiuc A., and Mandrekar P. Pattern recognition receptors: a contemporary view on liver diseases. Hepatology 44 (2006) 287-298
10. Naugler W.E., Sakurai T., Kim S., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317 (2007) 121-124
11. Seki E., De Minicis S., Osterreicher C.H., et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13 (2007) 1324-1332
12. Hemmi H., Takeuchi O., Kawai T., et al. A Toll-like receptor recognizes bacterial DNA. Nature 408 (2000) 740-745
13. Frances R., Zapater P., Gonzalez-Navajas J.M., et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 47 (2008) 978-985
14. Guarner C., Gonzalez-Navajas J.M., Sanchez E., et al. The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology 44 (2006) 633-639
15. Watanabe A., Hashmi A., Gomes D.A., et al. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 46 (2007) 1509-1518
16. Imaeda A.B., Watanabe A., Sohail M.A., et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest 119 (2009) 305-314
17. Gabele E., Muhlbauer M., Dorn C., et al. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun 376 (2008) 271-276
18. Adachi O., Kawai T., Takeda K., et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9 (1998) 143-150
19. Kodama Y., Kisseleva T., Iwaisako K., et al. c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology 137 (2009) 1467-1477 e5
20. Van Rooijen N., and Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174 (1994) 83-93
21. Kodama Y., Taura K., Miura K., et al. Antiapoptotic effect of c-Jun N-terminal Kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis. Gastroenterology 136 (2009) 1423-1434
22. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
23. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-4129
24. Miura K., Yoshino R., Hirai Y., et al. Epimorphin, a morphogenic protein, induces proteases in rodent hepatocytes through NF-kappaB. J Hepatol 47 (2007) 834-843
25. Bilzer M., Roggel F., and Gerbes A.L. Role of Kupffer cells in host defense and liver disease. Liver Int 26 (2006) 1175-1186
26. Ramadori G., and Armbrust T. Cytokines in the liver. Eur J Gastroenterol Hepatol 13 (2001) 777-784
27. Mariathasan S., Newton K., Monack D.M., et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430 (2004) 213-218
28. Brun P., Castagliuolo I., Di Leo V., et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 292 (2007) G518-G525
29. Wu W.C., Zhao W., and Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World J Gastroenterol 14 (2008) 313-317
30. Miele L., Valenza V., La Torre G., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49 (2009) 1877-1887
31. Farhadi A., Gundlapalli S., Shaikh M., et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 28 (2008) 1026-1033
32. Isoda K., Sawada S., Ayaori M., et al. Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice. J Biol Chem 280 (2005) 7002-7009
33. Nozaki Y., Saibara T., Nemoto Y., et al. Polymorphisms of interleukin-1 beta and beta 3-adrenergic receptor in Japanese patients with nonalcoholic steatohepatitis. Alcohol Clin Exp Res 28 8 suppl proc (2004) 106S-110S
34. Parsons C.J., Bradford B.U., Pan C.Q., et al. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology 40 (2004) 1106-1115
35. Yoshiji H., Kuriyama S., Miyamoto Y., et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 32 (2000) 1248-1254
36. Yoshiji H., Kuriyama S., Yoshii J., et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 36 (2002) 850-860
37. Dalpke A.H., Lehner M.D., Hartung T., et al. Differential effects of CpG-DNA in Toll-like receptor-2/-4/-9 tolerance and cross-tolerance. Immunology 116 (2005) 203-212
38. De Nardo D., De Nardo C.M., Nguyen T., et al. Signaling crosstalk during sequential TLR4 and TLR9 activation amplifies the inflammatory response of mouse macrophages. J Immunol 183 (2009) 8110-8118
39. Seki E., Tsutsui H., Nakano H., et al. Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta. J Immunol 166 (2001) 2651-2657
40. Imamura M., Tsutsui H., Yasuda K., et al. Contribution of TIR domain-containing adapter inducing IFN-beta-mediated IL-18 release to LPS-induced liver injury in mice. J Hepatol 51 (2009) 333-341
41. Inokuchi S., Aoyama T., Miura K., et al. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc Natl Acad Sci U S A 107 (2010) 844-849
42. Chitturi S., Abeygunasekera S., Farrell G.C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35 (2002) 373-379
43. Chitturi S., Farrell G., Frost L., et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?. Hepatology 36 (2002) 403-409
44. Fartoux L., Chazouilleres O., Wendum D., et al. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 41 (2005) 82-87
45. Camma C., Bruno S., Di Marco V., et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 43 (2006) 64-71
46. Ota T., Takamura T., Kurita S., et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 132 (2007) 282-293
47. Sakurai M., Takamura T., Ota T., et al. Liver steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver disease. J Gastroenterol 42 (2007) 312-317
48. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40 (2008) 1461-1465
49. Kantartzis K., Peter A., Machicao F., et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 58 (2009) 2616-2623
50. He S., McPhaul C., Li J.Z., et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 285 (2010) 6706-6715
51. Valenti L., Al-Serri A., Daly A.K., et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51 (2010) 1209-1217
52. Anstee Q.M., and Goldin R.D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87 (2006) 1-16